Cardiff Oncology Q2 net loss widens

Cardiff Oncology

29/07/2025 21:14

Overview

Cardiff Oncology Q2 net loss of $13.9 mln widens

Operating expenses rose due to clinical trial costs and new hires

Completed enrollment in Phase 2 trial for first-line RAS-mutated mCRC

Outlook

Cardiff Oncology projects cash runway into Q1 2027

Result Drivers

TRIAL ENROLLMENT - Completion of enrollment in Phase 2 CRDF-004 trial for first-line RAS-mutated mCRC

OPERATING EXPENSES - Increase due to clinical trial costs and new hires

POSITIVE TRIAL DATA - Announced positive data from onvansertib and paclitaxel trial in mTNBC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Royalty Revenue
$121,000
Q2 Net Income
Miss
-$13.94 mln
-$13.50 mln (8 Analysts)
Q2 Income from Operations
Miss
-$14.78 mln
-$14.10 mln (8 Analysts)
Q2 Basic EPS
-$0.21
Q2 Operating Expenses
$14.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $12.00, about 68.9% above its July 28 closing price of $3.73

Press Release: ID:nGNX41Hw4Q

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)